How are Vandetanib clinical trials progressing?

Vandetanib (Vandetanib) is a small molecule multi-target tyrosine kinase inhibitor (TKI) that mainly targets the RET, VEGFR and EGFR signaling pathways and is used to treat advanced or advanced medullary thyroid cancer (MTC; thyroid cancer). Since being approved by the US FDA in 2011, vandetanib has become one of the globally recognized targeted therapeutic drugs. In recent years, with the development of precision medicine, clinical research on vandetanib has continued to advance, and the research direction has gradually shifted from single-target treatment to combined treatment and exploration of resistance mechanisms.

In multiple overseas studies, vandetanib has shown the potential to extend progression-free survival (PFS) in patients with medullary thyroid cancer, especially for patients carrying RET mutations. Recent research has further focused on the differences in efficacy between different genetic subtypes, aiming to provide personalized treatment basis for patients with RET mutations, RAS mutations and no mutations. At the same time, some clinical trials have explored its combination with other targeted drugs, such as cabozantinib or a new generation of RET inhibitors, in order to improve efficacy and overcome drug resistance.

In the field of non-thyroid tumors, vandetanib has also been included in a number of exploratory studies. For example, in the experimental stages of malignant tumors such as small cell lung cancer, non-small cell lung cancer, and breast cancer, researchers hope to achieve a broader anti-tumor effect through its dual mechanisms of anti-angiogenesis and EGFR inhibition. Some preliminary results show that vandetanib can exert a synergistic effect in combination with immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies), suggesting that it has potential in the field of immune combination therapy in the future.

In addition, the drug resistance mechanism and dose optimization of vandetanib are still being studied clinically. Some patients experience activation of alternative signals other than the RET pathway after long-term medication, resulting in reduced drug sensitivity. To this end, new studies are exploring intermittent dosing strategies, combined anti-angiogenic drugs, and sequential treatment options using selective RET inhibitors. This strategy is thought to have the potential to prolong the overall duration of efficacy of vandetanib.

Reference materials:https://www.drugs.com/caprelsa.html